Perspective Therapeutics (NYSE:CATX) Now Covered by Analysts at Truist Financial

Truist Financial initiated coverage on shares of Perspective Therapeutics (NYSE:CATX) in a research note released on Wednesday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $21.00 price target on the stock.

Several other research analysts have also recently issued reports on CATX. Cantor Fitzgerald restated an overweight rating on shares of Perspective Therapeutics in a report on Monday, September 9th. Bank of America began coverage on Perspective Therapeutics in a research report on Thursday, July 25th. They issued a buy rating and a $24.00 target price for the company. Royal Bank of Canada cut their price target on Perspective Therapeutics from $29.00 to $27.00 and set an outperform rating on the stock in a research report on Friday, August 16th. Finally, Oppenheimer lowered their target price on shares of Perspective Therapeutics from $19.00 to $17.00 and set an outperform rating on the stock in a research report on Tuesday, August 13th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, Perspective Therapeutics presently has a consensus rating of Buy and a consensus target price of $20.00.

Perspective Therapeutics Stock Performance

Perspective Therapeutics stock opened at $12.57 on Wednesday. Perspective Therapeutics has a twelve month low of $2.20 and a twelve month high of $19.05. The stock’s fifty day moving average is $13.81.

Perspective Therapeutics (NYSE:CATX) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.04. The firm had revenue of $0.53 million during the quarter. Analysts predict that Perspective Therapeutics will post -0.86 EPS for the current year.

Hedge Funds Weigh In On Perspective Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Sykon Capital LLC boosted its holdings in shares of Perspective Therapeutics by 4.7% in the 2nd quarter. Sykon Capital LLC now owns 37,932 shares of the company’s stock valued at $378,000 after purchasing an additional 1,717 shares during the last quarter. Victory Capital Management Inc. acquired a new position in shares of Perspective Therapeutics during the 2nd quarter valued at $117,000. Point72 DIFC Ltd purchased a new stake in Perspective Therapeutics during the 2nd quarter worth $118,000. The Manufacturers Life Insurance Company acquired a new stake in Perspective Therapeutics in the 2nd quarter valued at $188,000. Finally, ZWJ Investment Counsel Inc. purchased a new position in Perspective Therapeutics in the first quarter valued at about $26,000. 54.66% of the stock is currently owned by institutional investors and hedge funds.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.